

Unravelling the facets-dependent behavior among H₂O₂, O₃ and oxygen vacancies on CeO_x and the promotion of peroxone reaction at acidic condition

Weirui Chen^{a,b,c,d}, Hengxi He^{†,a,b,c,d}, Ruini Zou^a, Yidan Chen^a, Xukai Li^{a,b,c,d}, Jing Wang^{a,b,c,d*}, Yiming Tang^{a,b,c,d},

Laisheng Li^{a,b,c,d*}

a School of Environment, South China Normal University, Guangzhou 510006, China

b Key Laboratory of Theoretical Chemistry of Environment, Ministry of Education, Guangzhou 510006, China

c Guangdong Provincial Engineering Technology Research Center for Drinking Water Safety, Guangzhou 510006, China

d Guangdong Provincial Key Lab of Functional Materials for Environmental Protection, Guangzhou 510006, China

Tel: +86-20-39310185, Fax: +86-20-39310187

† Both authors contributed equally to this work

* Corresponding author, E-mail: jing.wang@m.scnu.edu.cn (J. Wang)

* Corresponding author, E-mail: lsh@scnu.edu.cn (L. Li)

Table S1 HPLC condition for detecting selected PPCPs

Compound	Mobile phase (v/v)	Wavelength (nm)
Ketoprofen	Ultra-pure water: acetonitrile =55:45	220
Sulfamethoxazole	0.1% Acetic acid solution: methanol=70:30	272
Ibuprofen	0.1% formic acid : acetonitrile=75:25	220
Ciprofloxacin	5% Acetic acid solution: methanol 68:32	278
Lincomycin	0.02 M KH ₂ PO ₄ :acetonitrile:methanol=70:15:15	206
Chlortetracycline	0.01 M oxalic acid:acetonitrile:methanol=67:22:11	274
Sulfadimethoxine	Acetonitrile:water=60:40	270
Clofibrate acid	Methanol and 0.1% acetic solution =65:35	232
Bezafibrate	Methanol: acetonitrile:0.02% acetic solution =5:40:55	228
Chloramphenicol	Methanol: water=65:35	275
Sulpiride	Acetonitrile: ultra-pure water=5:95	290
Norfloxacin	0.01 M oxalic acid:acetonitrile:methanol=67:22:11	268
Trimethoprim	Acetonitrile: 0.1% formic solution=30:70	210
Tetracycline	Acetonitrile: 0.1 M oxalic acids =20:80	375
Carbamazepine	Methanol: ultra-pure water =80:20	280
Erythromycin	0.025 M phosphate: acetonitrile=40:60	210
Sulpiride	Acetonitrile: 0.1% formic solution =5:95	210
Ofloxacin	Methanol: 0.1% formic solution =5:95	278
Indomethacin	Methanol: ultra-pure water =65:35	265
Nalidixic acid	Acetonitrile: 0.1% formic solution=40:60	258
Diclofenac	Methanol:1% acetic solution=80:20	280

Table S2 Peaks information for Ce 3d

Samples	Peak	Fresh		Used	
		Position (eV)	Area	Position (eV)	Area
(100) CeO _x	v ₀	880.204	50775.45	880.204	87772.99
	v'	885.043	82871.38	885.043	140447.1
	u ₀	897.37	114700.1	897.37	103968.3
	u'	903.309	26068.37	903.309	43496.35
	v	882.058	195758.1	882.058	194512.2
	v''	888.121	34742.64	888.121	29644.68
	v'''	898.39	69984.29	898.39	115349.5
	u	900.502	97114.5	900.502	110819.6
	u''	906.808	34826.61	906.808	29504.58
	u'''	915.976	128004.6	915.976	151754.2
(110) CeO _x	v ₀	880.204	41127.36	880.204	78842.38
	v'	885.043	95141.88	885.043	93804.52
	u ₀	897.37	79611.05	897.37	94481.77
	u'	903.309	25721.39	903.309	29594.04
	v	882.058	141029.3	882.058	120803.6
	v''	888.121	25115.85	888.121	13808.67
	v'''	898.39	70154.78	898.39	63511.02
	u	900.502	76569.78	900.502	66263.52
	u''	906.808	31571.45	906.808	23748.45
	u'''	915.976	106440.6	915.976	93835.12
(111) CeO _x	v ₀	880.204	49674.59	880.204	0.101
	v'	885.043	71197.57	885.043	65945.88
	u ₀	897.37	69796.09	897.37	21184.06
	u'	903.309	18121.91	903.309	16354.01
	v	882.058	118140.1	882.058	137444.8
	v''	888.121	17662.12	888.121	22328.07
	v'''	898.39	69883	898.39	61756.55
	u	900.502	62171.24	900.502	81088.28
	u''	906.808	19654.78	906.808	19171.81
	u'''	915.976	100347.5	916.5	74319.62

Table S3 Peaks information for O 1s

Samples	Peak	Fresh		Used	
		Position (eV)	Area	Position (eV)	Area
(100) CeO _x	O _I	528.855	192164.5	529.001	244242.5
	O _{II}	531.593	26482.17	531.693	32091.54
(110) CeO _x	O _I	529.102	163541.8	529.156	181440.7
	O _{II}	531.364	40216.72	531.439	75884.52
(111) CeO _x	O _I	529.319	115716.5	529.405	158835.7
	O _{II}	531.834	25035.03	531.834	26089.17

Table S4 Reaction rate constants from first order kinetics fitting

	$k(\text{CeO}_x/\text{O}_3)$	$k(\text{H}_2\text{O}_2)$	$k(\text{CeO}_x/\text{O}_3/\text{H}_2\text{O}_2)$	η
Ketoprofen	0.015	0.001	0.074	4.43
Sulfamethoxazole	-0.112	-0.004	-0.264	2.27
Ibuprofen	-0.019	0.001	-0.039	2.21
Ciprofloxacin	-0.184	-0.010	-0.394	2.04
Lincomycin	-0.704	-0.010	-1.242	1.74
Chlortetracycline	-0.391	0.001	-0.554	1.42
Sulfadimethoxine	-0.119	-0.007	-0.176	1.40
Clofibric acid	0.024	0.002	0.036	1.39
Bezafibrate	0.059	0.000	0.081	1.36
Chloramphenicol	-0.068	-0.003	-0.085	1.21
Norfloxacin	-0.126	-0.010	-0.153	1.12
Trimethoprim	-0.137	-0.002	-0.153	1.10
Tetracycline	-0.395	-0.009	-0.422	1.05
Carbamazepine	-0.100	-0.011	-0.110	0.99
Erythromycin	-0.302	-0.001	-0.292	0.96
Sulpiride	-0.130	-0.002	-0.109	0.82
Ofloxacin	-0.096	-0.009	-0.096	0.91
Indomethacin	-0.092	-0.025	-0.101	0.86
Nalidixic acid	-0.031	-0.005	-0.032	0.88
Diclofenac	-0.216	0.000	-0.163	0.76

Figure captions

Fig.S1 XRD pattern of different CeO_x;

Fig.S2 TGA of different CeO_x;

Fig.S3 Influence of calcination temperature on activity of (111) CeO_x;

Fig.S4 N₂ adsorption-desorption isotherm of different CeO_x;

Fig.S5 Heterogeneous peroxone of OA by different CeO_x with same S_{BET} dosage;

Fig.S6 •OH concentration in different CeO_x/O₃/H₂O₂ processes;

Fig.S7 Influence of PO₄³⁻ on heterogeneous peroxone process;

Fig.S8 Change of Ramen pattern of (100) and (110) during peroxone process;

Fig.S9 Atomic coordination of (100), (110) and (111) CeO_x;

Fig.S10 Degradation of PPCPs by (111) CeO_x/H₂O₂/O₃ with promotion effect;

Reaction condition: pollutants concentration: 10 mg/L; catalyst dosage: 0.1 g/L; initial pH=4.2; reaction temperature: 298 K; ozone output: 100 mg/h; H₂O₂ dosage: 3.3 mg/L;

Fig.S11 Degradation of PPCPs by (111) CeO_x/H₂O₂/O₃ with similar effect;

Reaction condition: pollutants concentration: 10 mg/L; catalyst dosage: 0.1 g/L; initial pH=4.2; reaction temperature: 298 K; ozone output: 100 mg/h; H₂O₂ dosage: 3.3 mg/L;

Fig.S12 Degradation of PPCPs by (111) CeO_x/H₂O₂/O₃ with inhibition effect;

Reaction condition: pollutants concentration: 10 mg/L; catalyst dosage: 0.1 g/L; initial pH=4.2; reaction temperature: 298 K; ozone output: 100 mg/h; H₂O₂ dosage: 3.3 mg/L;

Fig.S1




Fig.S2




Fig.S3




Fig.S4




Fig.S5




Fig.S6




Fig.S7




Fig.S8




Fig.S9




Fig.S10




Fig.S11




Fig.S12

